MK-2060

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for MK-2060, covering 2024-06-06 to 2025-11-17. Get the full timeline:

Most recent: Clinical Trial Update: Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) [Phase 2]

See pricing